Adiponectin and resistin in liver fibrosis with diabetes
Part of Digestive system clinical trials.
This trial looks at whether certain proteins in your blood (adiponectin and resistin) are linked to liver scarring (fibrosis) in people who have type 2 diabetes and a liver condition called MASLD. It may help doctors understand if these blood tests can predict liver damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes that was diagnosed less than five years ago.
- You do not drink alcohol heavily.
- You do not have long-term (chronic) liver disease or abnormal liver function.
- You do not have a severe infection right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatments for liver scarring in people with overweight or related health issues. One group follows a special diet with restricted eating times, while the other takes a combination of two medications (naltrexone and bupropion). It aims to see which approach better improves liver fibrosis.
This study is checking people with type 2 diabetes for early signs of liver scarring (fibrosis) caused by MASLD, a common fatty liver condition. If you have diabetes and no known advanced liver damage, this screening could help find problems early.
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study tests a simple blood test (FIB-4) to check for liver scarring in people with type 2 diabetes. It may help find liver problems early so you can get the right care.
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
Hear when a new Hepatic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.